Disposable Process for cGMP Manufacture of Plasmid DNA - A low cost, disposable process for the manufacture of pDNA will aid in the development of vaccines. - BioPharm International


Disposable Process for cGMP Manufacture of Plasmid DNA
A low cost, disposable process for the manufacture of pDNA will aid in the development of vaccines.

BioPharm International Supplements

The use of validated and pharmacopoeia-compliant quality control assays is essential to demonstrate the effectiveness of the process to purify pDNA away from process-related impurities.4 The platform should be validated according to the cGMP guidelines and achieve a high quality of product to satisfy the current regulatory requirements.4,5

Figure 1
An outline of the design of the cGMP process for manufacturing pDNA vaccines is shown in Figure 1. Each step should be attributed a specific function.


Plasmid DNA is transfected into E.coli by heat-shock, and clones containing the pDNA are identified under a selective pressure present on the vector (such as an antibiotic marker or by regulation of an essential E. coli protein). In an industrial setting, a master cell bank (MCB) is laid down from a clone, which is then cultured in large-scale fermenters by fed-batch, high-cell density culture.6 We have demonstrated that it is possible to omit the clone selection or MCB steps and culture a randomly selected clone in low-tech disposable shaker flasks without compromising high pDNA yields (>3 mg pDNA per gram of wet weight E. coli). We are able to routinely produce up to 200 mg of pDNA in a culture volume of less than 4 L in 24 hours. High specific yields are favored over high volumetric yields (mg pDNA per liter of ferment) because they reduce the relative starting load of E. coli-sourced contaminants. The ferment is harvested by centrifugation into single-use plastic centrifuge bottles at late log for maximal pDNA yields. Because of cost, we decided not to use disposable fermenter systems or crossflow applications for this step.


Figure 2
Standard alkaline lysis methods must be optimized to ensure the efficient lysis of cells and subsequent removal of major contaminants such as genomic DNA and proteins.7 The lysis is performed in a plastic container containing a low-level outlet attached to prefiltration and 0.22 μM filtration devices. The whole assembly and container are autoclaved together before use. Addition of a secondary salt such as ammonium acetate or calcium chloride precipitates and removes RNA (up to 45% reduction in contaminating nucleic acid load observed).8 The secondary salt partitions the flocculent (precipitated material) in an upper layer away from the lysate, which enables the subsequent clarification of the lysate by dead-end filtration (Figure 2). The clarified lysate can be stored in a bioprocess container or can be pumped directly into the crossflow filtration container for the start of the purification step.

Figure 3
Figure 3 shows the complex nature of the lysate, which is known to contain large amounts of RNA, endotoxin, and trace amounts of contaminating genomic DNA, protein, and other non-supercoiled pDNA related isoforms. The pDNA constitutes less than 5% of the total mixture, which presents a challenge to purify the desired monomeric supercoiled pDNA to homogeneity from contaminants that have similar physiochemical properties. Supercoiled pDNA is tightly coiled and is widely accepted as being the therapeutically efficacious form, mainly due to its relatively small size compared to other isoforms.1

blog comments powered by Disqus



GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here